[1]
Lochmann D, Richardson T. Selective Serotonin Reuptake Inhibitors. Handbook of experimental pharmacology. 2019:250():135-144. doi: 10.1007/164_2018_172. Epub
[PubMed PMID: 30838457]
[2]
Kendrick T, Pilling S, Mavranezouli I, Megnin-Viggars O, Ruane C, Eadon H, Kapur N, Guideline Committee. Management of depression in adults: summary of updated NICE guidance. BMJ (Clinical research ed.). 2022 Jul 20:378():o1557. doi: 10.1136/bmj.o1557. Epub 2022 Jul 20
[PubMed PMID: 35858703]
[3]
Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C. Citalopram versus other anti-depressive agents for depression. The Cochrane database of systematic reviews. 2012 Jul 11:7(7):CD006534. doi: 10.1002/14651858.CD006534.pub2. Epub 2012 Jul 11
[PubMed PMID: 22786497]
Level 1 (high-level) evidence
[4]
Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram--a review of pharmacological and clinical effects. Journal of psychiatry & neuroscience : JPN. 2000 May:25(3):241-54
[PubMed PMID: 10863884]
[5]
Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. Journal of child and adolescent psychopharmacology. 1997:7(3):157-66
[PubMed PMID: 9466233]
Level 3 (low-level) evidence
[6]
Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001 May:34(3):85-90
[PubMed PMID: 11434404]
Level 1 (high-level) evidence
[7]
Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. International clinical psychopharmacology. 2002 May:17(3):103-7
[PubMed PMID: 11981350]
[8]
Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundström-Poromaa I, Yonkers K, Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Archives of women's mental health. 2013 Aug:16(4):279-91. doi: 10.1007/s00737-013-0346-y. Epub 2013 Apr 27
[PubMed PMID: 23624686]
Level 3 (low-level) evidence
[9]
McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. The Journal of clinical psychiatry. 2003 Jul:64(7):807-13
[PubMed PMID: 12934982]
[10]
English BA, Jewell M, Jewell G, Ambrose S, Davis LL. Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. Journal of clinical psychopharmacology. 2006 Feb:26(1):84-8
[PubMed PMID: 16415713]
[11]
Saleh R, Majzoub A, Abu El-Hamd M. An update on the treatment of premature ejaculation: A systematic review. Arab journal of urology. 2021:19(3):281-302. doi: 10.1080/2090598X.2021.1943273. Epub 2021 Aug 4
[PubMed PMID: 34552780]
Level 1 (high-level) evidence
[12]
Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, Mitchell PH, Skolarus LE, Whooley MA, Williams LS, American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Feb:48(2):e30-e43. doi: 10.1161/STR.0000000000000113. Epub 2016 Dec 8
[PubMed PMID: 27932603]
Level 2 (mid-level) evidence
[13]
Luo Y, Chaimani A, Kataoka Y, Ostinelli EG, Ogawa Y, Cipriani A, Salanti G, Furukawa TA. Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study. BMJ open. 2018 Dec 9:8(12):e023222. doi: 10.1136/bmjopen-2018-023222. Epub 2018 Dec 9
[PubMed PMID: 30530583]
Level 2 (mid-level) evidence
[14]
Hyttel J. Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Progress in neuro-psychopharmacology & biological psychiatry. 1982:6(3):277-95
[PubMed PMID: 6128769]
[15]
Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical pharmacokinetics. 1996 Dec:31(6):444-69
[PubMed PMID: 8968657]
[16]
Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurology international. 2021 Aug 5:13(3):387-401. doi: 10.3390/neurolint13030038. Epub 2021 Aug 5
[PubMed PMID: 34449705]
Level 3 (low-level) evidence
[17]
Chakrapani S, Eskander N, De Los Santos LA, Omisore BA, Mostafa JA. Neuroplasticity and the Biological Role of Brain Derived Neurotrophic Factor in the Pathophysiology and Management of Depression. Cureus. 2020 Nov 9:12(11):e11396. doi: 10.7759/cureus.11396. Epub 2020 Nov 9
[PubMed PMID: 33312794]
[18]
Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. British journal of clinical pharmacology. 2014 Aug:78(2):373-83. doi: 10.1111/bcp.12348. Epub
[PubMed PMID: 24528284]
[19]
Wagner E, Löhrs L, Siskind D, Honer WG, Falkai P, Hasan A. Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of psychopharmacology (Oxford, England). 2019 Apr:33(4):423-435. doi: 10.1177/0269881118822171. Epub 2019 Jan 30
[PubMed PMID: 30696332]
Level 1 (high-level) evidence
[22]
Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society, Danish Society of Obstetrics and Gynecology, Danish Paediatric Society, Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta psychiatrica Scandinavica. Supplementum. 2015:(445):1-28. doi: 10.1111/acps.12479. Epub
[PubMed PMID: 26344706]
[23]
Munk-Olsen T, Bergink V, Rommel AS, Momen N, Liu X. Association of Persistent Pulmonary Hypertension in Infants With the Timing and Type of Antidepressants In Utero. JAMA network open. 2021 Dec 1:4(12):e2136639. doi: 10.1001/jamanetworkopen.2021.36639. Epub 2021 Dec 1
[PubMed PMID: 34851402]
[24]
Temming LA, Cahill AG, Riley LE. Clinical management of medications in pregnancy and lactation. American journal of obstetrics and gynecology. 2016 Jun:214(6):698-702. doi: 10.1016/j.ajog.2016.01.187. Epub 2016 Feb 2
[PubMed PMID: 26844758]
[26]
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr:67(4):674-694. doi: 10.1111/jgs.15767. Epub 2019 Jan 29
[PubMed PMID: 30693946]
[27]
Hekmatjah J, Tareen K, Tareen RS. Citalopram-Associated Alopecia: A Case Report and Brief Literature Review. Current drug safety. 2019:14(2):167-170. doi: 10.2174/1574886314666190215115857. Epub
[PubMed PMID: 30767750]
Level 3 (low-level) evidence
[28]
Aboukarr A, Giudice M. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. The Canadian journal of hospital pharmacy. 2018 May-Jun:71(3):196-207
[PubMed PMID: 29955193]
[29]
Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991 Mar:41(3):450-77
[PubMed PMID: 1711447]
[30]
Beckwith AR. The precipitation of mania by citalopram in a patient with interferon-induced depression. Psychosomatics. 2008 Jul-Aug:49(4):362-3. doi: 10.1176/appi.psy.49.4.362-a. Epub
[PubMed PMID: 18621943]
[31]
Schult RF, Morris AJ, Picard L, Wiegand TJ. Citalopram overdose and severe serotonin syndrome in an intermediate metabolizing patient. The American journal of emergency medicine. 2019 Oct:37(10):1993.e5-1993.e6. doi: 10.1016/j.ajem.2019.06.038. Epub 2019 Jun 21
[PubMed PMID: 31257122]
[32]
Rahikainen AL, Vauhkonen P, Pett H, Palo JU, Haukka J, Ojanperä I, Niemi M, Sajantila A. Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions. International journal of legal medicine. 2019 Mar:133(2):353-363. doi: 10.1007/s00414-018-1927-0. Epub 2018 Sep 1
[PubMed PMID: 30173302]
[33]
Levin TT, Cortes-Ladino A, Weiss M, Palomba ML. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. General hospital psychiatry. 2008 Jul-Aug:30(4):372-7. doi: 10.1016/j.genhosppsych.2008.03.008. Epub
[PubMed PMID: 18585543]
Level 3 (low-level) evidence
[34]
Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ (Clinical research ed.). 2005 Sep 10:331(7516):529-30
[PubMed PMID: 16150746]
[35]
Zeiss R, Connemann BJ, Schönfeldt-Lecuona C, Gahr M. Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection. Frontiers in psychiatry. 2021:12():727687. doi: 10.3389/fpsyt.2021.727687. Epub 2021 Oct 21
[PubMed PMID: 34744821]
[36]
Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Primary care companion to the Journal of clinical psychiatry. 2001 Feb:3(1):22-27
[PubMed PMID: 15014625]
[37]
Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J. Severe skin complications in patients treated with antidepressants: a literature review. Postepy dermatologii i alergologii. 2014 May:31(2):92-7. doi: 10.5114/pdia.2014.40930. Epub 2014 Apr 22
[PubMed PMID: 25097474]
[38]
Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013 Jan-Feb:54(1):1-13. doi: 10.1016/j.psym.2012.11.001. Epub
[PubMed PMID: 23295003]
[39]
Shah SR, Park K, Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Current problems in cardiology. 2019 Mar:44(3):92-106. doi: 10.1016/j.cpcardiol.2018.04.002. Epub 2018 May 10
[PubMed PMID: 29784533]
[40]
Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. European journal of clinical pharmacology. 2021 Feb:77(2):233-239. doi: 10.1007/s00228-020-02990-1. Epub 2020 Sep 8
[PubMed PMID: 32901348]
[41]
Alotaibi MS, Yousuf AZ, Khan A, Alshammari NS. Late Presentation of Linezolid-Induced Serotonin Syndrome After Maprotiline and Mirtazapine Therapy: A Case Report. Clinical neuropharmacology. 2021 Mar-Apr 01:44(2):71-74. doi: 10.1097/WNF.0000000000000431. Epub
[PubMed PMID: 33443942]
Level 3 (low-level) evidence
[42]
Montgomery SA, Rasmussen JG, Lyby K, Connor P, Tanghøj P. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. International clinical psychopharmacology. 1992 Jun:6 Suppl 5():65-70
[PubMed PMID: 1431024]
[43]
Ford J, Thomas F, Byng R, McCabe R. Use of the Patient Health Questionnaire (PHQ-9) in Practice: Interactions between patients and physicians. Qualitative health research. 2020 Nov:30(13):2146-2159. doi: 10.1177/1049732320924625. Epub 2020 Jun 20
[PubMed PMID: 32564676]
Level 2 (mid-level) evidence
[44]
Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PloS one. 2020:15(2):e0229381. doi: 10.1371/journal.pone.0229381. Epub 2020 Feb 26
[PubMed PMID: 32101579]
Level 1 (high-level) evidence
[45]
Bobo WV, Angleró GC, Jenkins G, Hall-Flavin DK, Weinshilboum R, Biernacka JM. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Human psychopharmacology. 2016 May:31(3):185-92. doi: 10.1002/hup.2526. Epub 2016 Mar 21
[PubMed PMID: 26999588]
Level 1 (high-level) evidence
[46]
Moore MT, Anderson NL, Barnes JM, Haigh EA, Fresco DM. Using the GAD-Q-IV to identify generalized anxiety disorder in psychiatric treatment seeking and primary care medical samples. Journal of anxiety disorders. 2014 Jan:28(1):25-30. doi: 10.1016/j.janxdis.2013.10.009. Epub 2013 Nov 20
[PubMed PMID: 24334213]
[47]
Stein DJ, Khoo JP, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C, Bauer M, Bitter I, Mosolov SN, Olivier V, Matharan S, Picarel-Blanchot F, de Bodinat C. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2018 Aug:28(8):970-979. doi: 10.1016/j.euroneuro.2018.05.006. Epub 2018 Jul 6
[PubMed PMID: 30135032]
Level 1 (high-level) evidence
[48]
Macaluso M, Preskorn SH. Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing. Journal of psychiatric practice. 2018 Nov:24(6):416-419. doi: 10.1097/PRA.0000000000000345. Epub
[PubMed PMID: 30395549]
[49]
Zoofaghari S, Wong A, Kiarasi P, Gheshlaghi F. Massive Citalopram Overdose Associated with Recurrent Seizures and Bilateral Shoulder Dislocations. Journal of research in pharmacy practice. 2020 Jul-Sep:9(3):161-164. doi: 10.4103/jrpp.JRPP_20_24. Epub 2020 Oct 8
[PubMed PMID: 33489987]
[50]
Iqbal MM, Basil MJ, Kaplan J, Iqbal MT. Overview of serotonin syndrome. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 2012 Nov:24(4):310-8
[PubMed PMID: 23145389]
Level 3 (low-level) evidence